TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01087398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)
Description: For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin, Methotrexate (GVHD prophylaxis)
Description: * Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)
Study: NCT02466360

Intervention type: BEHAVIORAL
Intervention: Back Belief questionnaire

Intervention type: BEHAVIORAL
Intervention: QUEBEC scale

Intervention type: BEHAVIORAL
Intervention: Fear Avoidance beliefs questionnaire

Intervention type: BEHAVIORAL
Intervention: Visual analog scale

Intervention type: BEHAVIORAL
Intervention: individual interviews

Intervention type: BEHAVIORAL
Intervention: Focus groups
Study: NCT03716739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Cypionate 100 MG/ML
Description: 100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by intramuscular injection weekly for 12 weeks.
Study: NCT04097002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ORCA-010
Description: The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ORCA-010
Description: The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ORCA-010
Description: The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ORCA-010
Description: The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.
Study: NCT02664168

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Ag Surgical Dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Use Negative Pressure Wound Therapy (PICO)
Study: NCT03858114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate physical activity
Description: According to ACSM guidelines, mild-to-moderate Physical Activity (PA) will be established as ≤ 60% of the Heart Rate Reserve (HRR). Baseline HR will be registered for all participants for three days, and the mean data will be utilized. PA intervention will consist of three phases:~1. warm up (10 minutes), up to 40% of HRR, with slow, dynamic movements and stretching for principal muscular groups;~2. Active phase (45 minutes), from \>40% to 60% HRR, with static and dynamic exercises for postural control and spine mobility, and balance exercises, with activation of core muscles;~3. cool down (10 minutes), \< 40% of HRR, with cardiorespiratory cool-down exercises followed by relaxation, and post-stretch exercises to return muscles to a pre-exercises length.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cultural group program
Description: A cultural group program with 12-weeks thematic meetings on places of historical and artistic interest in the city of Cagliari, Sardinia, with one visit/week to the same sites. The participants will be accompanied by expert tour guides to museums, monuments, city parks and archeological sites.
Study: NCT00983021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Single, simultaneous dose of NN9068, injected s.c. (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single, simultaneous dose of NN1250, injected s.c. (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single, simultaneous dose of NN1250, injected s.c. (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Single, simultaneous dose of NN2211, injected s.c. (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single, simultaneous dose of NN2211, injected s.c. (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single, simultaneous dose of placebo, injected s.c. (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single, simultaneous dose of placebo, injected s.c. (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Single, simultaneous dose of placebo, injected s.c. (under the skin)
Study: NCT01708681

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lean seafood

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lean seafood
Study: NCT04845009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation
Description: progressive muscle relaxation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT01708681

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat, egg, milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meat, egg, milk
Study: NCT02258750

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
Study: NCT01237457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Description: Patients will receive 200mCi dose of 177Lu Dotatate
Study: NCT05455918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP treatment (paclitaxel/ifosfamide/cisplatin)
Description: Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2\~5 (total 6g/m2) Cisplatin 25mg/m2/day D2\~5 (total 100mg/m2)
Study: NCT00290771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib tablets
Description: Imatinib was supplied as 100 and 400 mg tablets by Novartis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib tablets
Description: Imatinib was supplied as 100 and 400 mg tablets by Novartis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea capsules
Description: Hydroxyurea was supplied locally as 500 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea capsules
Description: Hydroxyurea was supplied locally as 500 mg capsules.
Study: NCT02183480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin, medium dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin, high dose
Study: NCT03311139

Intervention type: DRUG
Intervention: Antithrombotic agents
Description: Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date

Intervention type: DRUG
Intervention: Antithrombotic agents
Description: Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date

Intervention type: DRUG
Intervention: Antithrombotic agents
Description: Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
Study: NCT02450448

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study: NCT02671903

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker: AV optimised, His pacing.
Description: Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
Study: NCT04319029

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical care plan
Description: The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study.
Study: NCT01025076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StomaphyX
Description: StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
Study: NCT04033887

Intervention type: DIAGNOSTIC_TEST
Intervention: 13 Rapid Diagnostic Tests and reference tests
Description: Rapid diagnostic tests:~1. HCV antibody test (under development); bioLytical Laboratories~2. DPP® HCV (under development); Chembio Diagnostic Systems~3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~4. Rapid Anti-HCV Test; InTec~5. First Response HCV Card Test; Premire Medical Corporation~6. Signal HCV Ver 3.0; Arkray healthcare~7. TRI DOT HCV; J. Mitra \& Co~8. Triplex HIV, HCV, HBsAg; Biosynex SA~9. Standard Q HCV Ab; SD Biosensor~10. HCV Hepatitis Virus Antibody Test; Artron Laboratories~11. SD Bioline HCV; Abbott Diagnostics~12. OraQuick HCV; OraSure~13. Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0

Intervention type: DIAGNOSTIC_TEST
Intervention: 13 Rapid Diagnostic Tests and reference tests
Description: Rapid diagnostic tests:~1. HCV antibody test (under development); bioLytical Laboratories~2. DPP® HCV (under development); Chembio Diagnostic Systems~3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~4. Rapid Anti-HCV Test; InTec~5. First Response HCV Card Test; Premire Medical Corporation~6. Signal HCV Ver 3.0; Arkray healthcare~7. TRI DOT HCV; J. Mitra \& Co~8. Triplex HIV, HCV, HBsAg; Biosynex SA~9. Standard Q HCV Ab; SD Biosensor~10. HCV Hepatitis Virus Antibody Test; Artron Laboratories~11. SD Bioline HCV; Abbott Diagnostics~12. OraQuick HCV; OraSure~13. Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0
Study: NCT01331382

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans- resveratrol
Description: All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans- resveratrol
Description: All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Trans- resveratrol
Description: All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (silica)
Description: All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (silica)
Description: All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (silica)
Description: All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
Study: NCT03458273

Intervention type: PROCEDURE
Intervention: Zero fluoroscopy ablation
Description: Catheter ablation for the treatment of atrial and ventricular arrhythmia - no fluoroscopy guidance

Intervention type: PROCEDURE
Intervention: Conventional ablation without 3D
Description: Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance only. 3D system (Every Ensite/Carto) is not allowed

Intervention type: PROCEDURE
Intervention: Conventional ablation with 3D
Description: Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance + 3D system support (Ensite/Carto)
Study: NCT03147014

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Maternal hyperoxygenation
Description: approximately 10-15 minutes of maternal hyperoxygenation
Study: NCT01804296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
Study: NCT04325581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 6 MG/ML
Description: Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline SC daily
Study: NCT04498013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclodynon
Description: Cyclodynon 1 tablet a day during 6 menthes period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyl modification
Description: Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyl modification
Description: Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.
Study: NCT03208855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: 8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
Study: NCT04193345

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Documentation of Maternal blood loss and neonatal outcome
Description: Comparing and monitoring the maternal blood loss and neonatal effect of delayed umbilical cord clamping and early umbilical cord clamping after delivery of the baby durin cesarean delivery in severe preeclampsia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Documentation of Maternal blood loss and neonatal outcome
Description: Comparing and monitoring the maternal blood loss and neonatal effect of delayed umbilical cord clamping and early umbilical cord clamping after delivery of the baby durin cesarean delivery in severe preeclampsia
Study: NCT04670458

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01529983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment
Description: The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
Study: NCT02141698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-438 Placebo
Description: TAK-438 placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-438 Placebo
Description: TAK-438 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole tablets
Study: NCT01453751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)
Description: ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.